21277-16-7 Usage
Uses
Used in Pharmaceutical Industry:
2-oxo-4-imidazolinecarboxylic acid is used as a therapeutic agent for its potential antioxidant and anti-inflammatory properties, which can contribute to the treatment and management of various conditions.
Used in Cardiovascular Disease Treatment:
In the field of cardiology, 2-oxo-4-imidazolinecarboxylic acid is utilized as a potential treatment for cardiovascular diseases, given its involvement in blood pressure regulation and its overall impact on heart health.
Used in Diabetes Management:
2-oxo-4-imidazolinecarboxylic acid is employed as a component in diabetes management, where its potential role in the treatment of the condition is being explored for improving the health outcomes of diabetic patients.
These applications highlight the versatility and potential of 2-oxo-4-imidazolinecarboxylic acid in different areas of healthcare, emphasizing the importance of continued research and development in this field.
Check Digit Verification of cas no
The CAS Registry Mumber 21277-16-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,2,7 and 7 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 21277-16:
(7*2)+(6*1)+(5*2)+(4*7)+(3*7)+(2*1)+(1*6)=87
87 % 10 = 7
So 21277-16-7 is a valid CAS Registry Number.
InChI:InChI=1/C4H6N2O3/c7-3(8)2-1-5-4(9)6-2/h2H,1H2,(H,7,8)(H2,5,6,9)
21277-16-7Relevant academic research and scientific papers
PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
-
, (2010/03/02)
The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.
Analogs of thyrotropin-releasing hormone
-
, (2008/06/13)
Novel tripeptides are disclosed. These tripeptides have anti-depressant activity and thyrotropin releasing hormone activity. Processes for preparing these tripeptides are also disclosed.
